

# PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 84511

Title: Low-dose Immunotherapy as a potentiator to increase the response with

Neo-Adjuvant Chemotherapy in Oral Cancers

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05122811

**Position:** Peer Reviewer

Academic degree: DDS, MSc

Professional title: Associate Professor

Reviewer's Country/Territory: Iran

Author's Country/Territory: India

Manuscript submission date: 2023-03-17

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-04-08 05:21

Reviewer performed review: 2023-04-16 07:26

Review time: 8 Days and 2 Hours

	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C:
Scientific quality	Good
	[ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair
	[ ] Grade D: No novelty
Creativity or innovation of	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair
this manuscript	[ ] Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

### SPECIFIC COMMENTS TO AUTHORS

Dear authors While appreciating your efforts, it is necessary to mention that: 1.In the "Keywords" section, please delete "NACT". In addition, it is better to write "Keywords" in alphabetical order. 2. The "Abstract" of the article is written exactly the same as the "Introduction". Please correct. 3.It is better to remove the title "LIMITATIONS" and the text you wrote for it, without a special title, comes in a paragraph. 4.If possible, enter one or more newer references (2022 and 2023). Good luck



# PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 84511

Title: Low-dose Immunotherapy as a potentiator to increase the response with

Neo-Adjuvant Chemotherapy in Oral Cancers

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05382317

**Position:** Peer Reviewer

Academic degree: FRCS (Hon), MD

Professional title: Doctor, Surgeon

Reviewer's Country/Territory: China

Author's Country/Territory: India

Manuscript submission date: 2023-03-17

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-05-01 07:00

Reviewer performed review: 2023-05-10 09:56

Review time: 9 Days and 2 Hours

	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C:
Scientific quality	Good
	[ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	<ul> <li>[ ] Grade A: Excellent [ Y] Grade B: Good [ ] Grade C: Fair</li> <li>[ ] Grade D: No creativity or innovation</li> </ul>
· · · · · · · ·	



Scientific significance of the conclusion in this manuscript	<ul> <li>[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair</li> <li>[ ] Grade D: No scientific significance</li> </ul>
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	<ul> <li>[ ] Accept (High priority)</li> <li>[ ] Accept (General priority)</li> <li>[ Y] Minor revision</li> <li>[ ] Major revision</li> <li>[ ] Rejection</li> </ul>
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous       [] Onymous         Conflicts-of-Interest: [] Yes       [Y] No

### SPECIFIC COMMENTS TO AUTHORS

Immunotherapy is a hot topic for cancer therapy. The suggestion of using fixed low-dose immunotherapy agents as a potentiator in standard neoadjuvant chemotherapy regimens for oral cancer is an interesting proposition. Further research is needed to explore the role of immunotherapy in the comprehensive treatment of advanced oral cancer.